A Phase 3 interventional study of cilomilast in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 115 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-10-28.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's enrollment of 600 is above the median of 72 across 2,118 interventional studies indexed under Lung Diseases.
Browse Lung Diseases studies →GlaxoSmithKline is the lead sponsor of 3,561 studies on the registry; 116 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
Drug: cilomilast
measure of lung function and quality of life in patients with COPD
exacerbations in patients with COPD
Showing the first 100 of 115 sites.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline